Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.
Palvella Therapeutics Trading Up 2.6 %
Shares of PVLA traded up $0.71 during trading hours on Friday, reaching $28.14. The company's stock had a trading volume of 455,224 shares, compared to its average volume of 62,057. The company has a market cap of $315.76 million, a price-to-earnings ratio of -2.33 and a beta of 0.54. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27. The firm has a 50 day moving average of $18.78.
Analyst Upgrades and Downgrades
PVLA has been the topic of a number of research reports. TD Cowen initiated coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a "buy" rating and a $44.00 target price on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an "overweight" rating for the company. Scotiabank started coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $42.75.
Get Our Latest Research Report on Palvella Therapeutics
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Further Reading
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
